|
|
|
|
| Gain insight into leading CDMOs’ available capacity, capabilities, and timelines for biologic API development at the Large Molecule Drug Substance session of the Outsourced Pharma Capacity Update (Oct. 7). This virtual event highlights cell line development, fermentation, purification, and scale-up strategies — critical for producing high-quality biologics. Engage through short, interactive presentations and connect with CDMOs ready to support your pipeline needs. Open to biopharma companies, consultants, and investors seeking development and manufacturing partners. Save your spot today! |
|
|
|
|
By John W. Claud and Robert A. Dormer — Hyman, Phelps, & McNamara | FDA Commissioner Marty Makary has promised to end the so-called "double standard" of announced overseas inspections. Does the agency have the resources? | |
|
|
|
|
| Optimizing CDMO Tech Transfer | Article | By Vladas Algirdas Bumelis, Prof., André Markmann, Ph.D., and Dominic Chow, Ph.D., Northway Biotech | Pitfalls exist at every step when attempting to replicate a production process, whether a process is being scaled for commercialization, reproduced at the same scale at an additional site, or transferred to another CDMO. Learn the challenges associated with tech transfers and how to overcome them. |
|
|
|
|
| Site-Specific Conjugation For Next-Gen ADCs | Poster | Abzena | Unlock the full potential of your ADCs with a site-specific conjugation platform that delivers unmatched stability, homogeneity, and therapeutic performance. |
|
|
|
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
